development of new therapeutic approach to diabetes mellitus using human pancreatic duct cells

利用人胰管细胞开发糖尿病新治疗方法

• 批准号: 20591042
• 负责人: YATOH Shigeru
• 金额: $ 3万
• 依托单位: University of Tsukuba
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2008
• 资助国家: 日本
• 起止时间: 2008 至 2010
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-20591042/
• 关键词: インスリン; 再生医療; 膵島; 糖尿病治療; インクレチン; 膵島移植

We tried to induce human pancreatic duct cells into insulin-producing cells, which can be used to treat diabetic patients. Though duct cell fraction is got when islet transplantation, it is usually thrown away. As a result of our study to evaluate various factors and conditions to induce differentiation, it was suggested that glucagon-like peptide-1 (GLP-1) increased insulin-producing cells. Furthermore, expression of neurogenin-3 (ngn-3) was elevated in this process of differentiation. This result suggested that the process might mimic physiological differentiation because transient expression of ngn-3 was observed when stem/progenitor cells were induced into mature pancreatic B cells.

我们试图将人的胰管细胞诱导为胰岛素分泌细胞，这种细胞可以用于治疗糖尿病患者。虽然在胰岛移植时得到了导管细胞分数，但通常会被丢弃。由于我们的研究评估了诱导分化的各种因素和条件，结果表明胰升糖素样肽-1(GLP-1)增加了胰岛素产生细胞。此外，在分化过程中，神经原蛋白-3(NGN-3)的表达升高。这一结果提示，当干细胞/祖细胞被诱导为成熟的胰腺B细胞时，NGN-3的瞬时表达可能是模拟生理分化的过程。